Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

H&O What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]

Emerging Therapeutic Targets in Follicular Lymphoma

H&O What is the objective of the Wendel Laboratory? HGW We are interested in understanding the genetic and biologic mechanisms that lead to cancer in […]